People: GeneNews Ltd (GNWSF.PK)

GNWSF.PK on OTC Markets Group - US Other OTC and Grey Market

0.89USD
17 May 2013
Price Change (% chg)

$-0.05 (-5.17%)
Prev Close
$0.94
Open
$0.89
Day's High
$0.89
Day's Low
$0.89
Volume
1,000
Avg. Vol
3,732
52-wk High
$1.01
52-wk Low
$0.43

Search Stocks

Summary

Name Age Since Current Position

Rory Riggs

 2009 Independent Chairman of the Board

Gailina Liew

 2010 President, Chief Operating Officer, General Counsel, Corporate Secretary, Director

Heiner Dreismann

 59 2008 Interim Chief Executive Officer, Lead Director

Leslie Auld

 2010 Chief Financial Officer, Treasurer

Karl Wassmann

 2011 Executive Vice President - US Corporate Development

Harry Glorikian

 2008 Independent Director

James Howard-Tripp

 2002 Independent Director

Garth MacRae

 2000 Independent Director

David Sable

 2009 Independent Director
» Insider Trading

Biographies

Name Description

Rory Riggs

 Mr. Rory B. Riggs is Independent Chairman of the Board of GeneNews Limited. He is the Managing Member of Balfour LLC, an investment management company. Mr. Riggs is the past President of Biomatrix, Inc., a NYSE listed company which developed and marketed one of the viscosupplementation products in the United States, Synvisc®, for the treatment of osteoarthritis. Prior to Biomatrix, Mr. Riggs was Chief Executive Officer of RF&P Corporation and was also a Managing Director of PaineWebber Inc. Mr. Riggs holds a B.A. from Middlebury College, Vermont, and an MBA from the Graduate School of Business, Columbia University, New York.

Gailina Liew

 Ms. Gailina J. Liew, LLB, MBA is President, Chief Operating Officer, General Counsel, Corporate Secretary, Director of GeneNews Limited. Ms. Liew is the President and Chief Operating Officer for GeneNews and a member of the Company’s Strategy Committee and executive team. She joined the Company in 2000 as General Counsel and has held roles of increasing responsibility. Ms. Liew is currently responsible for the general management and operations of GeneNews. Prior to GeneNews, Ms. Liew was Corporate Counsel for the Ontario Lead Investment Fund, a joint public-private venture capital fund. Ms. Liew earned a B.Sc. degree in Molecular Genetics and Molecular Biology from the University of Toronto, an LLB degree from the University of Western Ontario and a joint MBA degree from the Kellogg School of Management, Northwestern University and the Schulich School of Business, York University. She is a licensed member of the Law Society of Upper Canada and also acts as General Counsel and Corporate Secretary for GeneNews.

Heiner Dreismann

 Dr. Heiner Dreismann, Ph.D., is Interim Chief Executive Officer, Lead Director of GeneNews Limited. He is the former President and CEO of Roche Molecular Systems (RMS), a division of F. Hoffmann-La Roche Ltd. and the company that pioneered molecular diagnostics in the clinical diagnostic arena. Dr. Dreismann led the introduction of polymerase chain reaction-based tests in Europe as early as 1992 and witnessed first hand the industry growth over the last two decades. During his tenure as CEO, RMS annual sales increased strongly and the portfolio of tests and hardware sales were greatly expanded. Prior to being appointed CEO, Dr. Dreismann held other senior positions within Roche Diagnostics in the areas of Global Business Development, Business Unit Manager for Polymerase Chain Reaction and Microbiology, as well as R&D positions in microbiology and infectious diseases, and in manufacturing.

Leslie Auld

 Ms. Leslie Auld is Chief Financial Officer and Treasurer of GeneNews Limited. Ms. Auld began her professional career in 1991 with PriceWaterhouseCoopers. She later joined Helix BioPharma Corp. where she progressed from Controller to Chief Financial Officer. In 2004, she joined Luminex Diagnostics (formerly TM BioScience Corp.) as Senior Director of Finance, where she focussed on finance and operations during a period of growth and then held a pivotal role in the transaction that took TM BioScience private when it was acquired by Luminex. Ms. Auld joined Attwell Capital Inc. (formerly Fralex Therapeutics) as Chief Financial Officer in 2007. She left that position in June 2009 but continued to support Attwell and other issuers in a consulting capacity. Ms. Auld was initially retained by GeneNews on January 1, 2010, as a financial consultant. A Chartered Accountant, Ms. Auld graduated with an Honours Bachelor of Science, Pharmacology & Toxicology from the University of Western Ontario, and has a Master of Business Administration degree from the University of Toronto.

Karl Wassmann

Harry Glorikian

 Mr. Harry A. Glorikian is Independent Director of GeneNews Limited., since April 2008.Mr.Glorikian heads Scientia Advisors with 20 years of experience in the healthcare and life science industries. He is known worldwide in helping companies streamline their operations and accelerate their growth. Having held senior management positions at Applied Bio Systems, Signet Laboratories, in Massachusetts, and at X-Cell Laboratories, Inc., in California, Mr. Glorikian has a deep commercial background in diagnostics, molecular biology, proteomics, cellular biology and biodefense. His unique understanding of technologies, operations and strategy from both customer and industry player perspectives has shaped Scientia's sophisticated framework and proprietary analytic tools. A sHealt ought-after speaker, Mr. Glorikian has addressed the National Institutes of h, Molecular Medicine Tri-Conference and other audiences, worldwide. He has authored numerous articles for industry publications, appeared on CBS Evening News and been quoted by Dow Jones, the Boston Globe, BioWorld Today, Los Angeles Times, London Independent, Medical Device Daily, Science Magazine and many other media outlets. Harry holds an MBA from Boston University and a BA in Biology from San Francisco State University. He serves on many advisory boards and is an avid inventor who has several patents and patents pending in the US and abroad.

James Howard-Tripp

 Mr. James R. Howard-Tripp is Independent Director of GeneNews Ltd., since 2002. Mr. Howard-Tripp has specialized in the research, development and launch of innovative pharmaceutical products and the growth and development of the companies that research and market them. He has been involved in the management (GD Searle, Wyeth-Ayerst) and creation of (Allelix, Labopharm, Dermacor) several companies. He has 13 years experience as a President and CEO and has sat on multiple Boards, most as Chairman. Most recently as President and CEO of Labopharm he oversaw the research, development and approval of 3 products, the launch of 2, with the lead product marketed in 19 countries (total end user sales approx $100 million). During his tenure the company raised >$250 million in the public markets (US IPO $112 million in 2006) and achieved >$100 million in deal revenue (partners Sanofi-Aventis, Purdue Pharma, Merck Inc, Grunenthal, Angelini, Esteve). Additionally, he has served on various scientific and industry committees as well as several not-for-profit boards.

Garth MacRae

 Mr. Garth A.C. MacRae is Independent Director of GeneNews Limited. Mr. MacRae is a Director of Dundee Corporation, a merchant bank and financial services company, since 1991. Mr. MacRae is a Chartered Accountant, having received his designation in Manitoba in 1957 and has been a member of the Ontario Institute of Chartered Accountants since 1970. In addition to being a Director of GeneNews and of Dundee Corporation, Mr. MacRae is a director of a number of other public and private companies.

David Sable

 Dr. David B. Sable, M.D., is Independent Director of GeneNews Limited, since April 2009. David Sable – Director Dr. Sable directs healthcare and life science investing for the Special Situations Funds and is portfolio manager of the Special Situations Life Sciences Fund. After graduating from the Wharton School and the University of Pennsylvania School of Medicine, completing a residency in obstetrics and gynecology at New York Hospital - Cornell Medical Center, a fellowship in reproductive endocrinology at Brigham and Women's Hospital in Boston, and clinical practice at Harvard Medical School and MIT, he co-founded the Institute for Reproductive Medicine and Science at Saint Barnabas Medical Center in New Jersey. After leaving clinical medicine, Dr. Sable managed a proprietary healthcare portfolio at Deutsche Bank before joining the Special Situations group. Dr. Sable teaches Entrepreneurship in Biotechnology at Columbia University and has lectured on healthcare investing, policy, and biotechnology business development at the Wharton School, NYU, and Rutgers. Dr. Sable is currently a member of the GeneNews’ Audit Committee.

Basic Compensation

Name Fiscal Year Total

Rory Riggs

 --

Gailina Liew

 306,801

Heiner Dreismann

 148,823

Leslie Auld

 181,666

Karl Wassmann

 74,646

Harry Glorikian

 --

James Howard-Tripp

 --

Garth MacRae

 --

David Sable

 --
As Of 30 Dec 2011

Options Compensation

Name Options Value

Rory Riggs

 0 0

Gailina Liew

 629,991 693,000

Heiner Dreismann

 0 0

Leslie Auld

 0 0

Karl Wassmann

 0 0

Harry Glorikian

 0 0

James Howard-Tripp

 0 0

Garth MacRae

 0 0

David Sable

 0 0

Insider Trading

» Full list on Insider Trading
Search Stocks